Passage Bio (NASDAQ:PASG) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Passage Bio (NASDAQ:PASG) had its price target raised by analysts at Chardan Capital from $6.00 to $21.00. They now have a "buy" rating on the stock.
Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights [Yahoo! Finance]
Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights
Passage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference